Rheumatology Advance Access originally published online on January 6, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2004; 43: 315-320
Rheumatology Vol. 43 No. 3 (c) British Society for Rheumatology 2003; all rights reserved
Clinical |
Maintenance of remission with leflunomide in Wegener's granulomatosis
Department of Rheumatology, University of Schleswig-Holstein, Campus Luebeck, Rheumaklinik Bad Bramstedt GmbH, Bad Bramstedt, Germany.
Correspondence to: E. Reinhold-Keller, Poliklinik für Rheumatologie des Universitätsklinikums Schleswig-Holstein, Campus Luebeck, Rheumaklinik Bad Bramstedt GmbH, Oskar-Alexander-Strasse 26, D-24576 Bad Bramstedt, Germany. E-mail: RKeller{at}rheuma-zentrum.de
Objective. To investigate the safety and efficacy of leflunomide plus low-dose prednisolone for the maintenance of remission in Wegener's granulomatosis (WG).
Methods. This was a Phase II, single-centre, open-label clinical investigation of patients with generalized WG treated with leflunomide after the induction of complete (n = 4) or partial (n = 16) remission by cyclophosphamide/prednisolone combination therapy. Leflunomide treatment was initiated at 20 mg/day and increased to 30 mg/day after 12 weeks and, in patients with partial remission, to 40 mg/day after 24 weeks. Concomitant low-dose prednisolone (
10 mg/day) was allowed during the study. In addition to the frequency of relapse, treatment efficacy was assessed by the standard measures of disease activity/extent.
Results. A total of 20 patients were enrolled in the trial. During a treatment period of up to 2.5 yr (median 1.75 yr, range 1–2.5 yr), one patient had a major relapse and required retreatment with cyclophosphamide/prednisolone. Eight patients had minor relapses that were successfully treated by dose increases to 40 mg/day leflunomide. Disease activity remained unchanged for the duration of the study. The most frequently reported adverse events were mild respiratory infection (40%), arthralgia (35%) and hypertension (35%); dry skin, nail disorder and diarrhoea were each reported by 30% of patients. Despite the aggressive pretreatment with cyclophosphamide, adverse events with leflunomide treatment at the higher dose (30–40 mg/day) were comparable with those seen with the standard dose (20 mg/day) for rheumatoid arthritis patients.
Conclusion. Leflunomide appears to be safe and well tolerated for the maintenance of complete or partial remission of WG. The results of this pilot study encourage further controlled trials comparing leflunomide with alternative remission maintenance therapies.
KEY WORDS: Wegener's granulomatosis, Leflunomide, Prednisolone, Remission, Maintenance therapy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Chikura, S. Lane, and J. K. Dawson Clinical expression of leflunomide-induced pneumonitis Rheumatology, September 1, 2009; 48(9): 1065 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Bosch, A. Guilabert, G. Espinosa, and E. Mirapeix Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review JAMA, August 8, 2007; 298(6): 655 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jayne Leflunomide versus methotrexate in Wegener's granulomatosis Rheumatology, July 1, 2007; 46(7): 1047 - 1048. [Full Text] [PDF]
|
|
|
|
|
|
C. Metzler, N. Miehle, K. Manger, C. Iking-Konert, K. de Groot, B. Hellmich, W. L. Gross, E. Reinhold-Keller, and for the German Network of Rheumatic Diseases Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis Rheumatology, July 1, 2007; 46(7): 1087 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sebastiani, D. Giuggioli, E. Vesprini, A. Caruso, and C. Ferri Successful treatment with leflunomide of arthritis in systemic sclerosis patients Rheumatology, September 1, 2006; 45(9): 1175 - 1176. [Full Text] [PDF]
|
|
|
|
|
|
D. R. Thickett, A. G. Richter, N. Nathani, G. D. Perkins, and L. Harper Pulmonary manifestations of anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis Rheumatology, March 1, 2006; 45(3): 261 - 268. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Hogan, R. J. Falk, H. Chin, J. Cai, C. E. Jennette, J. C. Jennette, and P. H. Nachman Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic Antibody-Associated Small-Vessel Vasculitis Ann Intern Med, November 1, 2005; 143(9): 621 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E N van Roon, T L T A Jansen, M A F J van de Laar, M Janssen, J P Yska, R Keuper, P M Houtman, and J R B J Brouwers Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis Ann Rheum Dis, April 1, 2005; 64(4): 569 - 574. [Abstract] [Full Text] [PDF]
|
|